Europe rejects stem cell patent

The European Patent Office (EPO) issued its final ruling last week rejecting a much-contested embryonic stem cell patent -- a decision that will likely be cheered by researchers and jeered by biotechs. The patent covered technology developed by linkurl:James Thomson,;http://ink.primate.wisc.edu/~thomson/ a University of Wisconsin researcher, to culture primate embryonic stem cells derived from pre-implantation embryos. In last week's ruling, the EPO upheld a previous decision, made last summer,

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The European Patent Office (EPO) issued its final ruling last week rejecting a much-contested embryonic stem cell patent -- a decision that will likely be cheered by researchers and jeered by biotechs. The patent covered technology developed by linkurl:James Thomson,;http://ink.primate.wisc.edu/~thomson/ a University of Wisconsin researcher, to culture primate embryonic stem cells derived from pre-implantation embryos. In last week's ruling, the EPO upheld a previous decision, made last summer, that rejected the patent. Earlier this year the US Patent Office upheld this patent, in addition to two others dealing with derivation and replication of embryonic stem cells in culture. The three patents, filed by the Wisconsin Alumni Research Foundation (WARF) in 1995, were reexamined, beginning in October, 2006, when challenges were brought by the Public Patent Foundation in New York and the Foundation for Taxpayer and Consumer Rights (FTCR) in Los Angeles. The two organizations argued that the patents impede stem cell research, and that other researchers before Thomson had developed the technology. In linkurl:a statement;http://www.epo.org/topics/news/2008/20081127.html from the EPO regarding the current decision, the Enlarged Board of Appeals said that under the European Patent Convention, "it is not possible to grant a patent for an invention which necessarily involves the use and destruction of human embryos." "I can imagine there will be sighs of relief," Robin Lovell-Badge, head of stem cell biology and developmental genetics at the National Institute for Medical Research, told the linkurl:Guardian.;http://www.guardian.co.uk/science/2008/nov/27/embryonic-stem-cells-patent "There are going to be lots of other biotech companies interested in either applications for the cells or deriving products from the cells, or using the cells in screening methodology." However, some said the decision could be a setback for biotech companies involved in developing embryonic stem cell technology. The EPO ruling could apply to some 200 other pending patent applications in Europe, linkurl:PharmaTimes reported.;http://www.pharmatimes.com/WorldNews/article.aspx?id=14845 However, the EPO ruling did state that the decision did not apply in general to the patentability of human stem cells. David Earp, chief patent counsel for Geron -- a stem cell biotech with several pending patent applications in Europe -- told PharaTimes that he his confident the ruling only applies to WARF patents and the agency will move quickly to address Geron's remaining applications.Related stories: linkurl:Stem cell patents final in US, debated in Europe;http://www.the-scientist.com/blog/display/54772/ linkurl:Stem cell patents upheld;http://www.the-scientist.com/blog/display/54419/ linkurl:USPTO upholds stem cell patent;http://www.the-scientist.com/blog/display/54389/ linkurl:WARF stem cell patents challenged;http://www.the-scientist.com/news/display/25037/
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio